GENinCode provides genomic testing for the prevention, diagnosis, and treatment of cardiovascular disease. Harnessing the power of both monogenic and polygenic risk assessment to combat the world’s most prevalent health problem.
Cardiovascular disease (CVD) is is the leading cause of death and disability worldwide accounting for 1 in every 4 deaths in the United States. CVD is a broad disease classification including coronary artery disease such as angina and myocardial infarction often referred to as heart attack. CVD also includes stroke, heart failure, hypertension and other vascular heart diseases.
GENinCode provides advanced genomic technology, products and recommendations fully validated by our scientific and clinical team. Our goal is to provide doctors and health care practitioners with comprehensive health information that combines both traditional clinical measures with a patient’s unique genetic information to provide a comprehensive risk assessment and clinical recommendation to help decision-making.
Our technology helps select the optimal treatment pathway and informs and educates patients to become more aware of their cardiovascular risk helping patient adherence and empowerment to better manage their health throughout their lifetime.
GENinCode is a predictive genetics company that specializes in regulatory approved clinical genetic tests for the risk assessment and prevention of heart disease and ovarian cancer. Our team, culture and mission are focused on revolutionizing preventative medicine by delivering personalized genetic diagnosis and polygenic risk assessment to provide tailored preventive treatment.
Our clinical tests have been developed and validated on large multi-ancestry population datasets and published extensively in leading clinical journals. We use our digital proprietary software system ‘SITAB’ to combine a patient’s genetic profile with clinical risk factors to predict and prevent heart disease and for the surveillance of ovarian cancer.
As a Company we specialise in Polygenic risk scores (PRS) to estimate an individual’s genetic likelihood of developing disease by aggregating the effects of many genetic variations to detect the risk of disease earlier so that treatment can be targeted at prevention.
GEN inCode U.S. Inc.
5 Mason, Suite 200
Irvine, CA 92618
GENinCode UK Limited
Oxford Science Park,
John Eccles House
Robert Robinson Avenue
Oxford, OX4 4GP
GENinCode S.L.U.
Rambla Egara, 235,
ES- 08224
Terrassa-Barcelona
